New bronchoscopic option used for severe emphysema

New bronchoscopic option used for severe emphysema

(HealthDay)—Temple University Hospital has become the first center in the U.S. to perform bronchoscopic lung volume reduction using implantation of the Zephyr Endobronchial Valve (Zephyr EBV) to treat hyperinflation associated with severe emphysema. The hospital is also the first to offer training to U.S. physicians for care and management of patients who undergo this procedure.

The Zephyr EBV is placed using a bronchoscope and flexible delivery catheter. It functions as a one-way valve allowing the damaged lobe of the lung to deflate, reducing hyperinflation. The first procedure, lasting 45 minutes, was performed on Aug. 10.

The U.S. Food and Drug Administration granted pre-market approval to the Zephyr EBV, manufactured by Pulmonx Corp., on June 29 under its breakthrough devices designation.

"This first post-FDA approval is a turning point in our capabilities to treat severe using a minimally invasive bronchoscopic option," Gerard J. Criner, M.D., chair of thoracic medicine and surgery at Temple University, said in a statement. "We are very excited to be able to clinically offer this therapy to patients with who remain symptomatic despite optimal medical care."

More information: More Information

Copyright © 2018 HealthDay. All rights reserved.

Citation: New bronchoscopic option used for severe emphysema (2018, September 10) retrieved 29 May 2024 from
This document is subject to copyright. Apart from any fair dealing for the purpose of private study or research, no part may be reproduced without the written permission. The content is provided for information purposes only.

Explore further

FDA: Zephyr Endobronchial Valve approved for severe emphysema


Feedback to editors